Physician profile
Anton Christopher Daniel
NPI 1700856135
$14,889.06
in general payments reported to CMS, 2019-2025
54 companies · $1,793 in 2025
The $1,793 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,948 · 2020: $2,176 · 2021: $2,303 · 2022: $2,379 · 2023: $2,162 · 2024: $2,129 · 2025: $1,793.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,051 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,051.16 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,052.32 | 2019-2025 | Otezla, Repatha, Repatha |
| Glaxosmithkline, LLC. | $1,426.67 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $1,218.40 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $931.32 | 2019-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $884.95 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $819.24 | 2019-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $635.98 | 2019-2025 | Camzyos, Eliquis |
| Amarin Pharma, INC. | $589.87 | 2019-2023 | |
| Collegium Pharmaceutical, INC. | $568.52 | 2019-2025 | Xtampza, Belbuca |
| Novartis Pharmaceuticals Corporation | $513.41 | 2019-2025 | |
| Otsuka America Pharmaceutical, INC. | $505.34 | 2019-2025 | Rexulti, Nuedexta |
| Pfizer INC. | $460.48 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $376.76 | 2021-2025 | |
| Esperion Therapeutics, INC. | $310.89 | 2020-2025 | Nexletol |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $304.38 | 2022-2025 | Caplyta |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anton Daniel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.